@article{JECCM5459,
author = {Jiangbo Zhu and Qing Liu and Gaojian Cheng and Zhongheng Zhang and Xue Wang},
title = {A retrospective study of the effectiveness of ulinastatin in the treatment of sepsis},
journal = {Journal of Emergency and Critical Care Medicine},
volume = {4},
number = {0},
year = {2019},
keywords = {},
abstract = {Background: Ulinastatin (UTI) as a urinary trypsin inhibitor can inhibit the function of various enzymes. UTI has been shown to reduce the inflammatory response, suppress lymphocyte apoptosis, and improve the microcirculation, protecting the organs. However, there is no uniform recommended dose to use UTI on treating sepsis, and some studies indicate that UTI has dose-dependent effects, we aimed to explore the effects and appropriate dosage of UTI in sepsis treatment.
Methods: Patients with sepsis in the intensive care unit (ICU) of the First Affiliated Hospital of Xi’an Jiaotong University from January 2012 through December 2017 were enrolled. We collected basic data, treatments, and outcomes. All patients were divided into two groups: the UTI group and the control group. Data analysis was performed with the chi-square test, t-test, and Cox multifactor regression analysis.
Results: A total of 295 patients (181 males; mean age 59.98±17.78 years) were enrolled. Univariate Cox regression analysis showed that the hazard ratio (HR) for mortality with UTI treatment was 0.805 (95% confidence interval: 0.530–1.222, P>0.05). After adjustment, there are 13 factors that might affect prognosis with multivariable Cox regression analysis, the adjusted HR for mortality with UTI treatment was 0.560 (95% confidence interval: 0.346–0.906, P},
issn = {2521-3563}, url = {https://jeccm.amegroups.org/article/view/5459}
}